Welcome to Patents and Trademarks Guide
Hiv Drug Patents Article
. For a permanent link to this article, or to bookmark it for further reading, click here.
India - Patents (Amendment) Act, 2005
from: P.M.George KuttyThe Government of India has met the December 31 deadline for complying with its obligation to World Trade Organisation (WTO) under TRIPs agreement, by promulgating an Ordinance - The Patent (Amendment) Ordinance, 2004 followed by the Act - Patent (Amendment) Act, 2005.
Under TRIPS, India was required to introduce product patent where only process patent was permitted. Procedural changes were also required to be made as per Patent Co-operation Treaty (PCT). The new Act ensures adequate safeguards against misuse of patent rights and vests enough power with the Government to intervene and ensure that patented inventions are available for the public at an affordable price.
In nutshell, the most important changes are:
·Product Patent can be issued in respect of food, drugs and chemicals. Provisions of 'process patent' for these goods abolished.
·Provisions in respect of EMR (Exclusive Marketing Rights) abolished.
·Computer software per se is not patentable, but in combination with or embedded in hardware is patentable.
·Provision of 'acceptance of specification' and its advertisement have been deleted.
·Provision for pre-grant and post-grant opposition to the granting of a patent.
·Application for patent will be published in Official Journal. At that time opposition can be made on limited grounds but hearing is not mandatory.
·After grant of patent, opposition can be made within 12 months.
·Provision of sealing of patent omitted.
·Provision for acquisition of patent for public health purposes.
·Suit for infringement of patent cannot commence before date of publication of publication of the application.
·Penalties enhanced substantially.
About the Author
Registered Patent Attorney of www.pmgip.com
Hiv Drug Patents News
Salix Pharmaceuticals Reports 4Q2009 and FY2009 Results - MarketWatch (press release)
Salix Pharmaceuticals Reports 4Q2009 and FY2009 Results MarketWatch (press release) The patent should provide protection until August 2019. "During the year we secured the exclusive right in the United States to Lupin's bioadhesive drug ... |
Bristol-Myers CEO's 2009 compensation down 22 pct - The Associated Press
Bristol-Myers CEO's 2009 compensation down 22 pct The Associated Press The maker of blood thinner Plavix, schizophrenia treatment Abilify and HIV drugs Reyataz and Sustiva gave Cornelius a salary of $1.5 million, up just $12000 ... |
Gilead downgraded on concerns about key patents - BusinessWeek
Gilead downgraded on concerns about key patents BusinessWeek Analyst Shiv Kapoor said Gilead gets about half its revenue from sales of the HIV drug Viread, flu treatment Tamiflu, hepatitis B drug Hepsera, ... Gilead Sciences' Pipeline Could Choke Gilead dips on analyst's patent concerns Gilead Sciences (GILD) Downgrade Alert, Watch for 8.9% Technical Uptrend Reversal |
Drug Makers Decry Indian Patent Law - Wall Street Journal
Drug Makers Decry Indian Patent Law Wall Street Journal Top-selling, life-saving medicines, including the anticancer treatment Glivec from Novartis SA; anticancer drug Tarceva from Roche SA; and HIV medicine ... Indian patent system draws more pharma ire |
Global Fund Reports On Progress Toward UN Health Goals - Intellectual Property Watch (blog)
Global Fund Reports On Progress Toward UN Health Goals Intellectual Property Watch (blog) And second-line treatments are needed for both HIV/AIDS and tuberculosis. There are new TB drugs in the pipeline, said Marcos Espinal, executive director of ... |
Gilead Set to Benefit From Newest HIV Drug - Seeking Alpha (blog)
Gilead Set to Benefit From Newest HIV Drug Seeking Alpha (blog) ... which last year made $5.84 billion from selling its HIV drugs, is facing patent expiries of up to 90% of its revenues between 2017 and 2021. ... |
Bristol-Myers to Plans to Sell Five New Drugs by 2012 - BusinessWeek
 Washington Post | Bristol-Myers to Plans to Sell Five New Drugs by 2012 BusinessWeek Sales of the HIV treatment Sustiva are also expected to fall by $800 million from 2014 to 2015, according to Steve Scala, an analyst with Cowen & Co. ... Bristol-Myers Squibb to Highlight Strong Pipeline and Execution of BioPharma ... Bristol-Myers Forecasts Post-Plavix Earnings Above Estimates - Update Bristol-Myers post-Plavix outlook exceeds views |